Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0085580 (essential hypertension)
 14,686 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In a multicenter, double-blind comparison of acebutolol and hydrochlorothiazide in patients with mild to moderate essential hypertension (diastolic blood pressure, 95 to 114 mm Hg) in 182 and 178 patients, respectively, each agent reduced systolic and diastolic pressures to a similar significant degree: acebutolol, 15.9 and 14.9 mm Hg; hydrochlorothiazide, 15.2 and 13.3 mm Hg (p less than 0.001 vs baseline). Acebutolol significantly reduced heart rate by 8.9 bpm at the end of dose titration (p = 0.001), with no further decrease seen during maintenance. Fourteen patients on each treatment regimen were discontinued from the study because of side effects. However, significantly more hydrochlorothiazide patients experienced side effects of arrhythmia, anorexia, and flatulence; in addition, more hydrochlorothiazide patients developed abnormal levels of serum glucose, uric acid, blood urea nitrogen, serum potassium, and chloride. In a single-center study of patients who remained hypertensive while receiving diuretics, six of nine patients receiving acebutolol concomitantly with a diuretic responded (seated diastolic blood pressure reduced below 90 mm Hg), whereas no patients receiving placebo and diuretic concomitantly responded (p less than 0.01). Patients taking both acebutolol and diuretic had significant reductions in diastolic blood pressure (11 mm Hg) and heart rate (16 bpm) compared with those taking diuretic alone (p less than 0.05, less than 0.01) and those taking both placebo and diuretic (p less than 0.05). No significant side effects were noted. Acebutolol is as effective as hydrochlorothiazide as monotherapy for mild to moderate essential hypertension and, in addition, is effective when added to a diuretic in patients who remain hypertensive while taking diuretics.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Comparison of acebutolol and hydrochlorothiazide in essential hypertension. 285 81

A double-blind multicenter study compared oral acebutolol (n = 182) with hydrochlorothiazide (n = 178) in the treatment of mild to moderate essential hypertension (diastolic blood pressure 95 to 114 mm Hg). Both agents produced significant and comparable reductions in systolic, diastolic, and mean arterial blood pressures of 15.9, 14.9, and 15.3 mm Hg on acebutolol, and 15.2, 13.3, and 11.8 mm Hg on hydrochlorothiazide (p = 0.001). Acebutolol induced a significant reduction in resting heart rate of 9.3 bpm (p = 0.001) from baseline. The mean effective doses of acebutolol and hydrochlorothiazide were 757 and 68 mg, respectively. Significantly fewer patients on acebutolol experienced arrhythmia, anorexia, and flatulence, although an equal number of patients (14) in each group discontinued therapy prematurely due to side effects. More hydrochlorothiazide-treated patients developed abnormalities in the levels of serum glucose, uric acid, blood urea nitrogen (BUN), serum potassium, and chloride. No clinically significant trends in laboratory parameters were seen on acebutolol, although a small number of patients (11 on acebutolol and 3 on hydrochlorothiazide) developed asymptomatic positive antinuclear antibody (ANA) tests of low titer. The data show that acebutolol is as effective as hydrochlorothiazide in the treatment of hypertension, is as well tolerated, and produces fewer biochemical abnormalities.
 ...
PMID:Comparative hypotensive effects of acebutolol and hydrochlorothiazide in patients with mild to moderate essential hypertension: a double-blind multicenter evaluation. 351 50